Your shopping cart is currently empty

PDM-631 is a selective and orally active inhibitor of PDE2A with the ability to penetrate the blood-brain barrier. It demonstrates potent inhibitory activity against recombinant PDE2A in humans and rats, with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex and is suitable for research on schizophrenia and neurodegenerative diseases.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | PDM-631 is a selective and orally active inhibitor of PDE2A with the ability to penetrate the blood-brain barrier. It demonstrates potent inhibitory activity against recombinant PDE2A in humans and rats, with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex and is suitable for research on schizophrenia and neurodegenerative diseases. |
| Targets&IC50 | PDE2A:1.5 nM (human) |
| Molecular Weight | 392.38 |
| Formula | C19H19F3N4O2 |
| Cas No. | 2095312-08-4 |
| Smiles | [C@@H](CC1=CC=C(OC(F)(F)F)C=C1)(C)N2C3=C(C(=N2)C4CC4)C(=O)N=C(C)N3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.